Skip to main content
Harm Reduction Journal logoLink to Harm Reduction Journal
. 2025 Aug 19;22:143. doi: 10.1186/s12954-025-01296-8

Tribally-affiliated syringe services programs in the United States: a brief report

Sean T Allen 1,, Edmund Keane 1, Clinton Alexander 2, Sharon Day 3, Philomena Kebec 4, Andrea Medley 5, Frank Johnson 2, Pam Hughes 6, Brooklynn Barney 5, Melissa Walls 5
PMCID: PMC12362947  PMID: 40826458

Abstract

Background

Few studies have examined the implementation of syringe services programs (SSPs) that serve Indigenous people who inject drugs in the United States (US). There are 574 Federally-recognized tribes in the US, each characterized by unique traditions, values, and customs. Given the diversity of tribes, better understanding SSP implementation in Native contexts first requires examining the degree to which tribes in the US implemented these programs.

Objective

This research describes the number of SSPs that are affiliated with Federally-recognized tribes in the US.

Methods

From July to September 2022, we conducted an online search of all 574 Federally-recognized tribes to determine how many had affiliated SSPs. We downloaded a list of Federally-recognized tribes from the Bureau of Indian Affairs (BIA) and conducted Boolean searches on Google for the name of each tribe and SSPs. Our searches included several synonyms for SSPs, including “needle exchange,” “syringe exchange,” and “harm reduction.” In instances where “harm reduction programs” were identified, we reviewed website contents to determine if the program was inclusive of a SSP. We considered SSPs to be affiliated with Federally-recognized tribe(s) if they were housed in a tribal health clinic or tribal organization, or via an explicit partnership with a Federally-recognized tribe.

Results

We identified 21 SSPs that were affiliated with Federally-recognized tribes. The majority (85.7%) of SSPs were affiliated with a single tribe. Eight of the SSPs also offered medications for opioid use disorder (MOUD) on-site (e.g., the SSPs operated out of health clinics that offered MOUD).

Conclusions

The results of this study demonstrate that there are at least 21 SSPs that are affiliated with Federally-recognized tribes in the US, with some serving multiple tribes. This research makes a noteworthy contribution to the public health literature given that no systematic exploration of the number of SSPs affiliated with tribes has been conducted. The scale of substance use inequities among Indigenous people underscores the critical importance of communities implementing and managing their own comprehensive harm reduction programs.

Keywords: Syringe services program, Indigenous, Harm reduction, Injection drug use, People who inject drugs

Background

Recent epidemiological data document alarming trends in overdose mortality and outbreaks of preventable infectious diseases (e.g., HIV, viral hepatitis) associated with substance use [16]. These data underscore the urgency of communities implementing evidence-based prevention and harm reduction initiatives. Although every community in the United States (US) has been affected by the addiction and overdose crisis, American Indian/Alaska Natives (AI/AN) have experienced disproportionate harms [711]. In recent years, overdose mortality has surged among AI/AN people [12]. Moreover, AI/AN people experienced the steepest percentage increase in overdose fatality rates from 2021 to 2022 of all demographic groups [12].

Substance use-use related morbidity has also increased as injection drug use (IDU) has become more prevalent [13]. Since 2004, data from the Centers for Disease Control and Prevention show that AI/AN communities have faced the highest rates of acute hepatitis C infection [14]. From 2018 to 2022, HIV diagnoses linked to IDU increased by 71% among AI/AN people in the US [15]. These IDU-associated inequities are driven in part by inadequate access to sterile injection equipment, resulting in high-risk injection practices (e.g., syringe sharing). According to National HIV Behavioral Surveillance data, approximately 30% of AI/AN people who inject drugs (PWID) without HIV reported having recently engaged in receptive syringe sharing [16]. Similarly, a recent study among a sample of reservation-based Indigenous PWID found that 65% reported having reused syringes [17].

There are many drivers of health inequities among Indigenous peoples, including historical traumas, stigmatization, forced cultural assimilation, systemic racism, and colonization [1821]. Nevertheless, cultural and communal practices have been shown to carry protective effects against substance use harms and negative effects associated with discrimination [2224]. Despite the many adversities and human rights violations Indigenous people have faced since the colonization of North America, they have consistently demonstrated resilience and perseverance. Given the central role that Indigenous culture plays in promoting health and healing, it is essential that community-level interventions be designed to reflect and honor cultural foundations. Furthermore, efforts to reduce substance use harms among Indigenous peoples should be supported through partnerships with local, state, Federal, and Tribal governments that prioritize the integration of evidence-based strategies with community values and culture. However, public health infrastructure is often inadequate in Native communities due to insufficient funding and settler-colonial governments failing to honor treaty and human rights obligations [25, 26].

Syringe services programs (SSPs) are an evidence-based strategy rooted in harm reduction and aim to meet people “where they are at” without requiring substance use cessation [2734]. These programs provide people who use drugs with low-threshold access to a variety of risk-reduction supplies, including sterile injection equipment and naloxone [28, 31, 32, 3436]. They may offer referrals for drug treatment and housing services [31]. SSPs were first implemented in the US in the 1980s in response to the AIDS crisis [34]. In 2022, there were more than 600 operational SSPs in the US [37]. Most urban counties had at least one SSP while only 6.7% of rural counties had operational programs [37]. No parallel lines of study have examined the degree to which American Indian tribes have implemented SSPs.

Extensive public health literature documents the public health benefits of SSPs [31]. For example, SSP implementation has been associated with lower odds of syringe sharing and reductions in IDU-associated HIV diagnoses, resulting in significant cost savings via averted treatment costs and improved quality of life [3841]. PWID who access SSP services are five times more likely to enter substance use treatment and approximately three times more likely to stop using substances [42]. SSPs also support the safe disposal of injection equipment [31, 32]. Notably, research has shown that SSPs are not linked to increases in drug use, criminal activity, or public syringe litter [31, 32].

While existing SSP-related literature is informative, very little of this work has focused on SSP implementation in Indigenous communities in the US. For example, studies have documented that Indigenous PWID report difficulties accessing SSP services [43, 44] Among the international literature, only limited study has focused on SSPs that serve Indigenous PWID, and these data are not directly translatable to the US given complex relationships between Indigenous peoples and local, state, and Federal entities [4550]. Further, there are 574 Federally-recognized tribes in the US, each characterized by unique traditions, values, and customs. Given the diversity of tribes, better understanding SSP implementation in Native contexts first requires examining the degree to which tribes implemented these programs. Unfortunately, no systematic study has been conducted to identify tribally-affiliated SSPs. As a first step in this line of inquiry, this research explores the number of SSPs that are affiliated with Federally-recognized tribes in the US.

Methods

From July to September 2022, we conducted an online search of all 574 Federally-recognized tribes to determine how many had affiliated SSPs. We downloaded a list of Federally-recognized tribes from the Bureau of Indian Affairs (BIA) [51]. We then conducted Boolean searches on Google for the name of each tribe and SSPs [52]. In conducting these searches, we used both formal and informal names of tribes (when applicable) to ensure robustness. Our searches also included several synonyms for SSPs, including “needle exchange,” “syringe exchange,” and “harm reduction.” In instances where “harm reduction programs” were identified, we reviewed website contents to determine if the program was inclusive of a SSP. We considered SSPs to be affiliated with Federally-recognized tribe(s) if they were housed in a tribal health clinic or tribal organization, or via an explicit partnership with a Federally-recognized tribe.

No SSPs or tribes were contacted as part of this research. Given that this research only used publicly accessible data, it did not constitute human subjects research and Institutional Review Board approval was not required. Nevertheless, we undertook steps to ensure our work was respectful of Tribal Nations. First, the co-authors of this manuscript include several individuals (CA, PK, SD, and FJ) who operate SSPs that serve Indigenous peoples. Our co-authors also include several individuals who have experiences pertaining to the provision of harm reduction services in Native contexts; as a result, they are acutely aware of the potential ramifications of unwanted attention to their work (e.g., stigmatization of substance use). Further, we did not name any tribe or affiliated SSP as naming requires careful consideration of potential downstream effects (e.g., unwanted attention to tribes and/or affiliated SSPs) and the explicit permission of tribes.

Results

We identified 21 SSPs that were affiliated with Federally-recognized tribes. The majority (85.7%) of SSPs were affiliated with a single tribe. Among SSPs affiliated with multiple tribes, one was based in a clinic that served persons from four Federally-recognized tribes and two programs operated out of tribal health consortia (i.e., organizations that provided healthcare services to persons from many different tribes). Eight of the SSPs also offered medications for opioid use disorder (MOUD) on-site (e.g., the SSPs operated out of health clinics that offered comprehensive healthcare services).

Discussion

The results of this study demonstrate that there are at least 21 SSPs that are affiliated with Federally-recognized tribes, with some serving multiple tribes. This research makes a noteworthy contribution to the public health literature given that no systematic exploration of the number of SSPs affiliated with tribes has been conducted. Further, the scale of substance use inequities among Indigenous people underscores the critical importance of communities implementing and managing their own comprehensive harm reduction programs that are anchored in local culture. Indeed, there is a movement toward Indigenizing harm reduction initiatives such that they not only meet people where they are at but also reconnect people to culture and work toward undoing the harms of colonization [53].

The low volume of tribally-affiliated SSPs may reflect the need for Indigenous people to combine SSPs, which most often reflect harm reduction and allopathic “western” approaches to health and well-being, with traditional Indigenous approaches for healing. Harm reduction aims to minimize adverse health, social, and legal consequences of substance use and does not require abstinence [29, 30]. Allopathic “western” approaches are generally individualistic and biologic in nature and encompass pharmacologic treatments for health conditions [5456]. In contrast, traditional Indigenous approaches are holistic and seek to meet the emotional, physical, spiritual, and mental health needs of people who seek care. Traditional Indigenous approaches are heterogeneously defined across Indigenous communities, but may include healing ceremonies, use of medicinal plants, song and dance, smudging and purification, storytelling, talking circles, and engaging with Elders [23, 5461]. Notably, Indigenous PWID may have goals that transcend all three approaches to health and well-being. For example, they may continue to use substances, potentially calling for harm reduction services, while also accessing MOUD (i.e., allopathic “western” services) and wanting to participate in traditional Indigenous ceremonies to meet their spiritual and mental health needs. As a result, the implementation of SSPs centered on holistically addressing the needs of Indigenous PWID may result in enhanced access to life-sustaining and health-promoting resources.

In some instances, tribally-affiliated SSPs have adopted program models that differ from other tribal programs. For example, in efforts to reduce barriers to service, some tribal SSPs do not require proof of tribal enrollment and serve a mixed-status population to ensure that their programs effectively reach PWID in the broader community [64]. Tribal SSPs may also emphasize outreach to incarcerated community members, as AI/AN are over-incarcerated in many states and incarceration is a major risk factor for drug overdose and other harms [62].

Integrating multiple approaches to health and wellbeing at SSPs that serve Indigenous people may carry unique challenges. For example, traditional Indigenous and allopathic “western” approaches reflect different belief systems [55, 63]. Further, allopathic “western” practitioners can be skeptical of traditional Indigenous approaches and discount their value [63]. Harm reduction also has tensions with traditional Indigenous and allopathic “western” approaches [64, 65]. For instance, some feel that harm reduction is in conflict with the goals of allopathic “western” approaches to drug dependence (e.g., MOUD), since abstinence is not necessarily the goal of harm reduction [6567]. At the same time, the integration of harm reduction and traditional Indigenous approaches to healing can be challenging as some teachings emphasize abstaining from psychotropic substances as a prerequisite for engaging in certain cultural and spiritual practices associated with healing [47, 68].

Although integrating multiple approaches to health can be challenging, there are numerous SSPs that successfully did so. For example, the SSP at the Indigenous Peoples Task Force (located in Minneapolis, Minnesota) integrates harm reduction (e.g., access to sterile injection equipment and naloxone, safer use counseling and education), allopathic “western” (e.g., MOUD referrals, HIV/STI testing and prevention services), and traditional Indigenous (e.g., ceremonial fires, alters with asemaa, cedar, and sage for client use) approaches [69]. The Indigenous Peoples Task Force also provides healthy meals that feature foods from traditional diets before colonization (e.g., wild rice, corn, berries, and buffalo or fish). Additionally, the Indigenous Peoples Task Force provides SSP clients with opportunities to visit with Elders. Future work should be conducted to learn from SSPs that center the voices of Indigenous people and holistically meet the needs of Native PWID.

Research has shown that SSPs tailored to Native PWID are able to provide public health services in ways that address unmet needs for multiple approaches to health and wellbeing. For example, the Gwayakobimaadiziwin Bad River Harm Reduction (a community center that operates a SSP on the Bad River Band of Lake Superior Chippewa reservation) conducted a qualitative exploration of their SSP operations and community needs among Indigenous PWID in 2019 [68]. Among their findings, Indigenous PWID reported being confronted with multiple barriers to accessing healthcare. Participants reported that healthcare providers did not understand the difficulties they experienced attending scheduled appointments due to housing instability and limited access to transportation and phone services. Participants also reported that they felt distanced from opportunities for traditional healing due to requirements for abstinence. These findings informed how the SSP subsequently adapted operations to align with cultural practices and worked to improve the provision of traditional Indigenous, allopathic “western,” and harm reduction services to Indigenous PWID [68]. Currently, the Gwayakobimaadiziwin Bad River Harm Reduction has an open-door policy for PWID, providing a comfortable space to access to harm reduction supplies (e.g., sterile injection equipment, naloxone), personal wellness needs (e.g., shower, laundry service, safe sleeping areas, food, phones, phone cards and bus passes) and support for accessing higher-level heathcare (e.g., peer support, rides to appointments, MOUD and in-patient treatment referrals, HIV/STI prevention and testing services). The program also provides PWID with access to Native medicines and opportunities to participate in Ojibwe healing ceremonies, and all aspects of service delivery are grounded in the seven teachings of the Ojibwe. This program has parallels to other tribally-affiliated SSPs that offer access to traditional medicines, sobriety feasts, referrals to spiritual leaders to conduct ceremonies, and harvests of medicinal herbs.

Although existing public health literature has gaps, there are clear indicators of Indigenous communities wanting enhanced access to SSP services. For example, a 2025 study conducted in a northern Midwest American Indian community found that 56% of people who had recently used drugs were willing to use an SSP if it were available [70]. In that Indigenous community, willingness to use an SSP was associated with recent methamphetamine use, having experienced or witnessed an overdose, having friends or family who use drugs, and younger age [70]. These findings have parallels to a qualitative study conducted among Indigenous PWID in which participants voiced positive attitudes and perceptions about SSP services, but noted that programs were difficult to access [43]. Another study conducted in rural Montana among Indigenous PWID found that 98% expressed interest in utilizing a harm reduction program [17]. Our findings, in conjunction with the literature, provide compelling evidence of the need for communities working to advance the public health of Indigenous PWID via enhanced access to SSPs.

Despite extensive evidence documenting the public health benefits of SSP implementation, domestic policies and funding priorities remain challenges. Broadly speaking, reservation-based public health services are severely underfunded. In part, this reflects a failure of the US government to honor treaties [25, 26]. Further, there are unique policy implications for tribes as they navigate the complex interplay between federal, state, and tribal regulations. Tribal Nations face challenges navigating sovereignty and overlapping legal systems that impact implementation of SSPs. Although federal guidelines permit SSPs, some states may still criminalize syringe possession, restrict access to naloxone, or impose limitations on point-of-contact or CLIA-waived rapid screening for HIV, HCV, or STIs. Public Law 83-280 (PL 280) limits tribal sovereignty by granting certain states criminal jurisdiction over tribal lands which oftentimes undermines tribal authority in enforcement of tribal laws and authority to govern public health initiatives, such as SSPs. These additional legal barriers significantly impact the implementation of SSPs in tribal communities by creating additional limitations and confusion over jurisdiction. Another example, under Public Law 93-638, the Indian Self-Determination and Education Assistance Act, some tribes rely entirely on the Indian Health Service for healthcare, limiting their ability to implement certain harm reduction strategies due to federal policy. Other tribes have assumed more direct control of their healthcare in which they must also comply with relevant state laws, which further shapes service delivery and access to care. These deficiencies of the US government paired with the lasting effects of colonization and historic traumas act independently and synergistically to drive health outcomes among Indigenous people. Reversing the inertia of the status quo requires systems level changes throughout the US and broader support for holistic service delivery to Indigenous PWID, including via SSPs. The influx of opioid settlement funding for states and counties provides a unique opportunity to right past wrongs through funding partnerships to eliminate drug-related disparities among AI/AN populations.

This research has several limitations that warrant consideration. First, our search strategy focused on identifying SSPs that were affiliated with Federally-recognized tribes. As a result, our findings likely underestimate the true number of SSPs that serve Indigenous people, particularly given that several tribes are not recognized by the US Federal Government. Additionally, our search strategy may not have accounted for Indigenous language terms related to SSPs, harm reduction, or specific traditional healing practices. Another limitation is that our search strategy did not lend itself to the identification of SSPs that served Indigenous people, but were not affiliated with a specific tribe or tribes; for instance, the SSP at the Indigenous Peoples Task Force primarily serves Indigenous people, but is not affiliated with a specific tribe. Another limitation is that tribes may not publicize their SSPs due to concerns about privacy or attracting unwanted attention (e.g., “not in my backyard” opposition). Further, they may have limited capacity to serve people who are not affiliated with the tribe. Another limitation is that we were unable to ascertain the volume of PWID the tribally-affiliated SSPs served and their associated geographic catchment areas. Future work exploring the reach of these programs may enhance our understanding of whether tribally-affiliated SSPs are accessed at greater rates than programs operating in predominantly “western” contexts. Finally, we did not contact tribes to solicit information about whether they had operational SSPs. While doing so might have helped identify additional SSPs without accessible information on the internet, it would have potentially conflicted with one or multiple tribes’ or tribal governments’ expectations for appropriate outreach. Federal and Constitutional protections for this sort of inquiry may be accepted by US tribes generally, but each tribe maintains systems to exercise self-governance and self-determination, which may include unique protections and protocols for engagement with outside researchers. Despite these limitations, this research enhances our understanding of tribally-affiliated SSPs in the US.

In conclusion, this research reports the number of tribally-affiliated SSPs in the US identified through a comprehensive search of publicly available sources. We found evidence of 21 SSPs affiliated with Federally-recognized tribes. Given the scale of substance use inequities, additional work is needed to better understand how to support tribal communities implement SSPs that are tailored to local contexts and priorities. Additional funding should be allocated by local, state, and Federal governments to support tribally-led initiatives to implement tailored harm reduction initiatives, including SSPs.

Acknowledgements

We are grateful to the CIRCLE Center of Excellence for support developing this manuscript.

Abbreviations

AI/AN

American Indian/Alaska native

SSP

Syringe services programs

PWID

People who inject Drugs

HIV

Human immunodeficiency virus

MOUD

Medications for opioid use disorder

CDC

Centers for disease control and prevention

IDU

Injection drug use

Author contributions

STA, EK, MW were involved in the conception of the study. EK led the online searches. All authors were involved in the interpretation of the findings. All authors were involved in drafting the manuscript. All authors reviewed and approved the final manuscript and agree to be held accountable for all aspects of the work.

Funding

STA and MW are supported by the Bloomberg American Health Initiative at Johns Hopkins University. Research reported in this publication was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number P50DA058619. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

This research did not constitute human subjects research and only utilized publicly accessible data.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Hess KL et al. Diagnoses of HIV infection in the United States and dependent areas, 2017. 29. 2018. https://stacks.cdc.gov/view/cdc/60911.
  • 2.CDC. Opioid Overdose: Centers for Disease Control and Prevention; 2020 [Available from: https://www.cdc.gov/drugoverdose/index.html.
  • 3.Centers for Disease Control and Prevention. (2020). Overdose deaths accelerating during COVID‑19. Available at: https://archive.cdc.gov/www_cdc_gov/media/releases/2020/p1218-overdose-deaths-covid-19.html.
  • 4.Centers for Disease Control and Prevention. Drug overdose deaths in the U.S. top 100,000 annually. 2021. Available at: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.html.
  • 5.Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2025. 10.15620/cdc/20250305008
  • 6.Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Qeadan F, Madden EF, Mensah NA, Tingey B, Herron J, Hernandez-Vallant A, et al. Epidemiological trends in opioid-only and opioid/polysubstance-related death rates among American Indian/Alaska Native populations from 1999 to 2019: a retrospective longitudinal ecological study. BMJ Open. 2022;12(5): e053686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Tipps RT, Buzzard GT, McDougall JA. The opioid epidemic in Indian Country. J Law Med Ethics. 2018;46(2):422–36. [DOI] [PubMed] [Google Scholar]
  • 9.Kebec P. The impact of fentanyl on American Indian and Alaskan Native communities. The Brookings Institution. 2024. Retrieved July 30, 2025, from https://www.brookings.edu/wp-content/uploads/2024/11/FP-20241127-fentanyl-native-communities-kebec.pdf.
  • 10.Schuler MS, Schell TL, Wong EC. Racial/ethnic differences in prescription opioid misuse and heroin use among a national sample, 1999–2018. Drug Alcohol Depend. 2021;221: 108588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Friedman JR, Hansen H. Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic. JAMA Psychiatr. 2022;79(4):379–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Spencer MR, Garnett MF, Miniño AM. Drug overdose deaths in the United States, 2002–2022. NCHS Data Brief, no 491. Hyattsville, MD: National Center for Health Statistics. 2024. 10.15620/cdc:135849
  • 13.Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report–United States, 2019. https://www.cdc.gov/hepatitis/statistics/2019surveillance/index.htm. Published May 2021.
  • 15.Centers for Disease Control and Prevention. (2024). Fast facts: HIV in the United States. Available at: https://www.cdc.gov/hiv/data-research/facts-stats/index.html
  • 16.Centers for Disease Control and Prevention. HIV Infection Risk, Prevention, and Testing Behaviors among Persons Who Inject Drugs—National HIV Behavioral Surveillance: Injection Drug Use, 23 U.S. Cities, 2018. HIV Surveillance Special Report 24. http://www.cdc.gov/hiv/library/reports/hivsurveillance.html. Published February 2020.
  • 17.Anastario M, FourStar K, Ricker A, Dick R, Skewes MC, Rink E. A preliminary needs assessment of American Indians who inject drugs in northeastern Montana. Harm Reduct J. 2017;14(1):22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.King M, Smith A, Gracey M. Indigenous health part 2: the underlying causes of the health gap. Lancet. 2009;374(9683):76–85. [DOI] [PubMed] [Google Scholar]
  • 19.Gameon JA, Skewes MC. Historical trauma and substance use among American Indian people with current substance use problems. Psychol Addict Behav. 2021;35(3):295–309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Pokhrel P, Herzog TA. Historical trauma and substance use among Native Hawaiian college students. Am J Health Behav. 2014;38(3):420–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wispelwey B, Tanous O, Asi Y, Hammoudeh W, Mills D. Because its power remains naturalized: introducing the settler colonial determinants of health. Front Public Health. 2023. 10.3389/fpubh.2023.1137428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wright S, Nebelkopf E, King J, Maas M, Patel C, Samuel S. Holistic system of care: evidence of effectiveness. Subst Use Misuse. 2011;46(11):1420–30. [DOI] [PubMed] [Google Scholar]
  • 23.Marsh TN, Coholic D, Cote-Meek S, Najavits LM. Blending aboriginal and western healing methods to treat intergenerational trauma with substance use disorder in aboriginal peoples who live in Northeastern Ontario, Canada. Harm Reduct J. 2015;12(1):14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Marsh TN, Marsh DC, Ozawagosh J, Ozawagosh F. The sweat lodge ceremony: a healing intervention for intergenerational trauma and substance use. Int Indig Policy J. 2018;9: 2. [Google Scholar]
  • 25.National Congress of American Indians. Appropriations & Budget. Retrieved July 30, 2025. Available at: https://www.ncai.org/policies/appropriations-and-budget.
  • 26.Deloria V. Behind the trail of broken treaties: an Indian declaration of independence. New York: Delacorte Press; 1974. [Google Scholar]
  • 27.Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(Suppl 2):S39–45. 10.1093/cid/cit296. (Erratumin:ClinInfectDis.2014Apr;58(8):1203.PMID:23884064;PMCID:PMC3722076). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(48):1337–41. [DOI] [PubMed] [Google Scholar]
  • 29.Harm Reduction International. What is harm reduction? Retrieved July 30, 2025. Available at: https://hri.global/what-is-harm-reduction/.
  • 30.Harm Reduction International. The Global State of Harm Reduction 2016. Harm Reduction International. 2016. Retrieved July 30, 2025. Available at: https://www.hri.global/files/2016/11/14/GSHR2016_14nov.pdf.
  • 31.Centers for Disease Control and Prevention. Syringe Services Programs (SSPs) Available at: https://www.cdc.gov/syringe-services-programs/php/index.html.
  • 32.Centers for Disease Control and Prevention. Safety and effectiveness of syringe services programs. 2024. Available at: https://www.cdc.gov/syringe-services-programs/php/safety-effectiveness.html
  • 33.Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, et al. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013;17(9):2878–92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Des Jarlais DC. Harm reduction in the USA: the research perspective and an archive to David Purchase. Harm Reduct J. 2017;14(1):51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Des Jarlais DC, Feelemyer J, McKnight C, Knudtson K, Glick SN. Is your syringe services program cost-saving to society? A methodological case study. Harm Reduct J. 2021;18(1):126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Des Jarlais DC, Marmor M, Paone D, Titus S, Shi Q, Perlis T, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet (London, England). 1996;348(9033):987–91. [DOI] [PubMed] [Google Scholar]
  • 37.Humphrey JL, Strack CN, Patel SV, Saunders ME, Wenger LD, Bluthenthal RN, et al. Implementation gaps in US syringe services programs, 2022. JAMA Netw Open. 2025;8(7):e2522764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ruiz MS, O’Rourke A, Allen ST. Impact evaluation of a policy intervention for HIV prevention in Washington, DC. AIDS Behav. 2016;20(1):22–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Ruiz MS, O’Rourke A, Allen ST, Holtgrave DR, Metzger D, Benitez J, et al. Using interrupted time series analysis to measure the impact of legalized syringe exchange on HIV diagnoses in Baltimore and Philadelphia. J Acquir Immune Defic Syndr. 2019;82(2):S148–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Nguyen TQ, Weir BW, Des Jarlais DC, Pinkerton SD, Holtgrave DR. Syringe exchange in the United States: a national level economic evaluation of hypothetical increases in investment. AIDS Behav. 2014;18(11):2144–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):235–48. [DOI] [PubMed] [Google Scholar]
  • 42.Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, Alexander ER. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treat. 2000;19(3):247–52. [DOI] [PubMed] [Google Scholar]
  • 43.Leston J, Crisp C, Lee MC, Rink E. Interviews with American Indian and Alaska Native people who inject drugs. Am Indian Alsk Native Ment Health Res. 2020;27(1):64–85. [DOI] [PubMed] [Google Scholar]
  • 44.Anastario M, Leston J, Crisp C, Lee C, Rink E. A qualitative study of services accessibility for indigenous persons who use injection drugs across three communities in the United States. J Ethn Subst Abuse. 2023;22(4):804–26. [DOI] [PubMed] [Google Scholar]
  • 45.Dell CA, Lyons TL, Cayer K, editors. The Role of ‘Kijigabandan’ and ‘Manadjitowin’ in understanding harm reduction policies and programs for aboriginal peoples. 2010.
  • 46.Wardman D, Quantz D. Harm reduction services for British Columbia’s First Nation population: a qualitative inquiry into opportunities and barriers for injection drug users. Harm Reduct J. 2006;3:30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Canadian Aboriginal AIDS Network & Interagency Coalition on AIDS and Development. Indigenous harm reduction = Reducing the harms of colonialism [Policy brief]. Canadian Substance Use Resource and Knowledge Exchange Centre (SURE). 2019. Available at: https://www.substanceuse.ca/sites/default/files/2021-04/Indigenous-Harm-Reduction-Policy-Brief.pdf.
  • 48.Wardman D, Quantz D. Harm reduction services for British Columbia’s First Nation population: a qualitative inquiry into opportunities and barriers for injection drug users. Harm Reduct J. 2006;3(1):30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Gray J. Harm reduction in the hills of northern Thailand. Subst Use Misuse. 1998;33(5):1075–91. [DOI] [PubMed] [Google Scholar]
  • 50.Gray J. Operating needle exchange programmes in the hills of Thailand. AIDS Care. 1995;7(4):489–99. [DOI] [PubMed] [Google Scholar]
  • 51.Bureau of Indian Affairs. Tribal Leaders Directory. U.S. Department of the Interior. Available at: https://www.bia.gov/service/tribal-leaders-directory.
  • 52.Google. Google. Available at: https://www.google.com/.
  • 53.First Nations Health Authority. Indigenous harm reduction. Available at: https://www.fnha.ca/what-we-do/mental-wellness-and-substance-use/harm-reduction-and-the-toxic-drug-crisis/indigenous-harm-reduction.
  • 54.Moghaddam JF, Momper SL. Integrating spiritual and Western treatment modalities in a Native American substance user center: provider perspectives. Subst Use Misuse. 2011;46(11):1431–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Horowitz S. American Indian health: integrating traditional Native healing practices and Western medicine. Altern Ther Health Med. 2012;18(1):24–30. 10.1089/act.2012.18103.22516848 [Google Scholar]
  • 56.Venner KL, Donovan DM, Campbell ANC, Wendt DC, Rieckmann T, Radin SM, et al. Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives. Addict Behav. 2018;86:111–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Koithan M, Farrell C. Indigenous Native American healing traditions. J Nurse Pract. 2010;6(6):477–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Redvers N, Blondin Bs. Traditional Indigenous medicine in North America: a scoping review. PLoS ONE. 2020;15(8): e0237531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Johnston SL. Native American traditional and alternative medicine. Ann Am Acad Pol Soc Sci. 2002;583:195–213. [Google Scholar]
  • 60.Rybak C, Decker-Fitts A. Understanding Native American healing practices. Counsel Psychol Q. 2009;22(3):333–42. [Google Scholar]
  • 61.Hirchak KA, Nadeau M, Vasquez A, Hernandez-Vallant A, Smith K, Pham C, et al. Centering culture in the treatment of opioid use disorder with American Indian and Alaska Native communities: contributions from a national collaborative board. Am J Community Psychol. 2022. 10.1002/ajcp.12620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Kebec P. The impact of fentanyl on American Indian and Alaskan Native communities. The Brookings Institution. 2024. Available at: https://www.brookings.edu/wp-content/uploads/2024/11/FP-20241127-fentanyl-native-communities-kebec.pdf.
  • 63.Carrie H, Mackey TK, Laird SN. Integrating traditional indigenous medicine and western biomedicine into health systems: a review of Nicaraguan health policies and Miskitu health services. Int J Equity Health. 2015;14:129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Goldstein SC, Spillane NS, Nalven T, Weiss NH. Harm reduction acceptability and feasibility in a North American indigenous reserve community. J Commun Psychol. 2022;50(8):3607–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Javadi R, Lagana K, Krowicki T, Bennett D, Schindler B. Attitudes toward harm reduction among substance use treatment professionals in Philadelphia. J Subst Use. 2022;27(5):459–64. [Google Scholar]
  • 66.Davis AK, Rosenberg H. Acceptance of non-abstinence goals by addiction professionals in the United States. Psychol Addict Behav. 2013;27(4):1102–9. [DOI] [PubMed] [Google Scholar]
  • 67.Rosenberg H, Davis AK. Differences in the acceptability of non-abstinence goals by type of drug among American substance abuse clinicians. J Subst Abuse Treat. 2014;46(2):214–8. [DOI] [PubMed] [Google Scholar]
  • 68.Kebec PRC, Conley A, Akerman S, Tochterman A. Expanding the circle of care a practical guide to syringe services for tribal and rural communities.
  • 69.Indigenous Peoples Task Force. Indigenous Peoples Task Force. Available at: https://indigenouspeoplestf.org/.
  • 70.Reid MC, Schneider KE, O’Rourke A, Conrad MA, Hughes PM, Walls ML, et al. Willingness to use syringe services programs in a Northern Midwest American Indian community. Harm Reduct J. 2025;22(1):123. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

No datasets were generated or analysed during the current study.


Articles from Harm Reduction Journal are provided here courtesy of BMC

RESOURCES